KMDA Q3 2020 Earnings — Kamada Ltd. Revenue & Financial Results | Market Cap Arena

KMDAKamada Ltd.

$495M

Q3 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$35M+6.8% YoY

Gross Profit

$15M42.0% margin

Operating Income

$8M22.0% margin

Net Income

$7M19.3% margin

EPS (Diluted)

$0.15

QoQ Revenue Growth

+6.8%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$4M

Stock-Based Comp.

$265,000

Balance Sheet

Total Assets

$206M

Total Liabilities

$30M

Stockholders' Equity

$177M

Cash & Equivalents

$52M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$35M	$33M	+6.8%
Gross Profit	$15M	$13M	+15.2%
Operating Income	$8M	$6M	+36.3%
Net Income	$7M	$6M	+17.4%